Targeting Transcription Factor Lysine Acetylation in Inflammatory Airway Diseases

References

• Barnes PJ . Immunology of asthma and chronic obstructive pulmonary disease . Nat. Rev. Immunol.8 ( 3 ), 183 – 192 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Kim HY , DeKruyffRH , UmetsuDT . The many paths to asthma: phenotype shaped by innate and adaptive immunity . Nat. Immunol.11 ( 7 ), 577 – 584 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Barnes PJ . The cytokine network in asthma and chronic obstructive pulmonary disease . J. Clin. Invest.118 ( 11 ), 3546 – 3556 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Caramori G , CasolariP , BarczykA , DurhamAL , Di StefanoA , AdcockI . COPD immunopathology . Semin. Immunopathol.38 ( 4 ), 497 – 515 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Barnes PJ . Inflammatory mechanisms in patients with chronic obstructive pulmonary disease . J. Allergy Clin. Immunol.138 ( 1 ), 16 – 27 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Keenan CR , SalemS , FietzER , GualanoRC , StewartAG . Glucocorticoid-resistant asthma and novel anti-inflammatory drugs . Drug Discov. Today17 ( 17–18 ), 1031 – 1038 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Telenga ED , KerstjensHA , PostmaDS , Ten HackenNH , van den BergeM . Inhaled corticosteroids in chronic obstructive pulmonary disease: a review . Expert Opin. Pharmacother.11 ( 3 ), 405 – 421 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Babu KS , KastelikJA , MorjariaJB . Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective . Br. J. Clin. Pharmacol.78 ( 2 ), 282 – 300 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rabe KF , HurdS , AnzuetoAet al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary . Am. J. Respir. Crit. Care Med.176 ( 6 ), 532 – 555 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Choudhary C , KumarC , GnadFet al. Lysine acetylation targets protein complexes and co-regulates major cellular functions . Science325 ( 5942 ), 834 – 840 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Choudhary C , WeinertBT , NishidaY , VerdinE , MannM . The growing landscape of lysine acetylation links metabolism and cell signalling . Nat. Rev. Mol. Cell Biol.15 ( 8 ), 536 – 550 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Allfrey VG , FaulknerR , MirskyAE . Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis . Proc. Natl Acad. Sci. USA51 , 786 – 794 ( 1964 ).
   PubMed Web of Science ®Google Scholar
• Strahl BD , AllisCD . The language of covalent histone modifications . Nature403 ( 6765 ), 41 – 45 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Dekker FJ , HaismaHJ . Histone acetyl transferases as emerging drug targets . Drug Discov. Today14 ( 19–20 ), 942 – 948 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Dekker FJ , van den BoschT , MartinNI . Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases . Drug Discov. Today19 ( 5 ), 654 – 660 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Mottamal M , ZhengS , HuangTL , WangG . Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents . Molecules20 ( 3 ), 3898 – 3941 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Bolden JE , PeartMJ , JohnstoneRW . Anticancer activities of histone deacetylase inhibitors . Nat. Rev. Drug Discov.5 ( 9 ), 769 – 784 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Yang XJ , SetoE . The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men . Nat. Rev. Mol. Cell Biol.9 ( 3 ), 206 – 218 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• de Ruijter AJ , van GennipAH , CaronHN , KempS , van KuilenburgAB . Histone deacetylases (HDACs): characterization of the classical HDAC family . Biochem. J.370 ( Pt 3 ), 737 – 749 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Parra M , VerdinE . Regulatory signal transduction pathways for class IIa histone deacetylases . Curr. Opin. Pharmacol.10 ( 4 ), 454 – 460 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Dali-Youcef N , LagougeM , FroelichS , KoehlC , SchoonjansK , AuwerxJ . Sirtuins: the ‘magnificent seven’, function, metabolism and longevity . Ann. Med.39 ( 5 ), 335 – 345 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Moser MA , HagelkruysA , SeiserC . Transcription and beyond: the role of mammalian class I lysine deacetylases . Chromosoma123 ( 1–2 ), 67 – 78 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Joshi P , GrecoTM , GuiseAJet al. The functional interactome landscape of the human histone deacetylase family . Mol. Syst. Biol.9 , 672 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Marks PA . The clinical development of histone deacetylase inhibitors as targeted anticancer drugs . Expert Opin. Investig. Drugs19 ( 9 ), 1049 – 1066 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wang H , DymockBW . New patented histone deacetylase inhibitors . Expert Opin. Ther. Pat.19 ( 12 ), 1727 – 1757 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Zagni C , FlorestaG , MonciinoG , RescifinaA . The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat . Med. Res. Rev. ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Roche J , BertrandP . Inside HDACs with more selective HDAC inhibitors . Eur. J. Med. Chem.121 , 451 – 483 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Chun P . Histone deacetylase inhibitors in hematological malignancies and solid tumors . Arch. Pharm. Res.38 ( 6 ), 933 – 949 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Fischer A . Targeting histone-modifications in Alzheimer’s disease. What is the evidence that this is a promising therapeutic avenue?Neuropharmacology80 , 95 – 102 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Royce SG , KaragiannisTC . Histone deacetylases and their inhibitors: new implications for asthma and chronic respiratory conditions . Curr. Opin. Allergy Clin. Immunol.14 ( 1 ), 44 – 48 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Grabiec AM , TakPP , ReedquistKA . Function of histone deacetylase inhibitors in inflammation . Crit. Rev. Immunol.31 ( 3 ), 233 – 263 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Wightman F , EllenbergP , ChurchillM , LewinSR . HDAC inhibitors in HIV . Immunol. Cell Biol.90 ( 1 ), 47 – 54 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Khan N , JeffersM , KumarSet al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors . Biochem. J.409 ( 2 ), 581 – 589 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Choi JH , OhSW , KangMS , KwonHJ , OhGT , KimDY . Trichostatin A attenuates airway inflammation in mouse asthma model . Clin. Exp. Allergy35 ( 1 ), 89 – 96 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Royce SG , DangW , YuanGet al. Effects of the histone deacetylase inhibitor, trichostatin A, in a chronic allergic airways disease model in mice . Arch. Immunol. Ther. Exp. (Warsz)60 ( 4 ), 295 – 306 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Banerjee A , TrivediCM , DameraGet al. Trichostatin A abrogates airway constriction, but not inflammation, in murine and human asthma models . Am. J. Respir. Cell Mol. Biol.46 ( 2 ), 132 – 138 ( 2012 ).
   PubMedGoogle Scholar
• Toki S , GoleniewskaK , ReissSet al. The histone deacetylase inhibitor trichostatin A suppresses murine innate allergic inflammation by blocking group 2 innate lymphoid cell (ILC2) activation . Thorax71 ( 7 ), 633 – 645 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Hou X , WanH , AiXet al. Histone deacetylase inhibitor regulates the balance of Th17/Treg in allergic asthma . Clin. Respir. J.10 ( 3 ), 371 – 379 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Zhang HP , WangL , FuJJ , FanT , WangZL , WangG . Association between histone hyperacetylation status in memory T lymphocytes and allergen-induced eosinophilic airway inflammation . Respirology21 ( 5 ), 850 – 857 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Ren Y , SuX , KongLet al. Therapeutic effects of histone deacetylase inhibitors in a murine asthma model . Inflamm. Res.65 ( 12 ), 995 – 1008 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Barnes PJ , AdcockIM , ItoK . Histone acetylation and deacetylation: importance in inflammatory lung diseases . Eur. Respir. J.25 ( 3 ), 552 – 563 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Ito K , CaramoriG , LimSet al. Expression and activity of histone deacetylases in human asthmatic airways . Am. J. Respir. Crit. Care Med.166 ( 3 ), 392 – 396 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Cosio BG , MannB , ItoKet al. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma . Am. J. Respir. Crit. Care Med.170 ( 2 ), 141 – 147 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Su RC , BeckerAB , KozyrskyjAL , HayglassKT . Altered epigenetic regulation and increasing severity of bronchial hyperresponsiveness in atopic asthmatic children . J. Allergy Clin. Immunol.124 ( 5 ), 1116 – 1118 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Butler CA , McQuaidS , TaggartCCet al. Glucocorticoid receptor beta and histone deacetylase 1 and 2 expression in the airways of severe asthma . Thorax67 ( 5 ), 392 – 398 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Gunawardhana LP , GibsonPG , SimpsonJL , PowellH , BainesKJ . Activity and expression of histone acetylases and deacetylases in inflammatory phenotypes of asthma . Clin. Exp. Allergy44 ( 1 ), 47 – 57 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Stefanowicz D , LeeJY , LeeKet al. Elevated H3K18 acetylation in airway epithelial cells of asthmatic subjects . Respir. Res.16 , 95–015 – 0254-y ( 2015 ).
   Web of Science ®Google Scholar
• Rajendrasozhan S , YangSR , KinnulaVL , RahmanI . SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease . Am. J. Respir. Crit. Care Med.177 ( 8 ), 861 – 870 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Ito K , ItoM , ElliottWMet al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease . N. Engl. J. Med.352 ( 19 ), 1967 – 1976 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Hodge G , JersmannH , TranHBet al. Lymphocyte senescence in COPD is associated with decreased histone deacetylase 2 expression by pro-inflammatory lymphocytes . Respir. Res.16 , 130–015 – 0287–2 ( 2015 ).
   Web of Science ®Google Scholar
• Tan C , XuanL , CaoS , YuG , HouQ , WangH . Decreased histone deacetylase 2 (HDAC2) in peripheral blood monocytes (PBMCs) of COPD patients . PLoS ONE11 ( 1 ), e0147380 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Barnes PJ . Glucocorticosteroids: current and future directions . Br. J. Pharmacol.163 ( 1 ), 29 – 43 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Hew M , BhavsarP , TorregoAet al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma . Am. J. Respir. Crit. Care Med.174 ( 2 ), 134 – 141 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Kobayashi Y , BossleyC , GuptaAet al. Passive smoking impairs histone deacetylase-2 in children with severe asthma . Chest145 ( 2 ), 305 – 312 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lee KY , ItoK , HayashiR , JazrawiEP , BarnesPJ , AdcockIM . NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription . J. Immunol.176 ( 1 ), 603 – 615 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Barnes PJ . Alveolar macrophages as orchestrators of COPD . COPD1 ( 1 ), 59 – 70 ( 2004 ).
   PubMedGoogle Scholar
• Caramori G , OatesT , NicholsonAGet al. Activation of NF-kappaB transcription factor in asthma death . Histopathology54 ( 4 ), 507 – 509 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Edwards MR , BartlettNW , ClarkeD , BirrellM , BelvisiM , JohnstonSL . Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease . Pharmacol. Ther.121 ( 1 ), 1 – 13 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Chen L , FischleW , VerdinE , GreeneWC . Duration of nuclear NF-kappaB action regulated by reversible acetylation . Science293 ( 5535 ), 1653 – 1657 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Chen L- , MuY , GreeneWC . Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB . EMBO J.21 ( 23 ), 6539 – 6548 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Kiernan R , BrèsV , NgRWMet al. Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65 . J. Biol. Chem.278 ( 4 ), 2758 – 2766 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Yeung F , HobergJE , RamseyCSet al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase . EMBO J.23 ( 12 ), 2369 – 2380 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Sato T , KotakeD , HiratsukaM , HirasawaN . Enhancement of inflammatory protein expression and nuclear factor Kappab (NF-Kappab) activity by trichostatin A (TSA) in OP9 preadipocytes . PLoS ONE8 ( 3 ), e59702 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Rosato RR , KollaSS , HockSKet al. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway . J. Biol. Chem.285 ( 13 ), 10064 – 10077 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Imre G , GekelerV , LejaA , BeckersT , BoehmM . Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation . Cancer Res.66 ( 10 ), 5409 – 5418 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Dai Y , RahmaniM , DentP , GrantS . Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation . Mol. Cell. Biol.25 ( 13 ), 5429 – 5444 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Zhang ZY , SchluesenerHJ . HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis . Prostate72 ( 1 ), 90 – 99 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zhang ZY , SchluesenerHJ . Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model . J. Neuropathol. Exp. Neurol.72 ( 3 ), 178 – 185 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Choo QY , HoPC , TanakaY , LinHS . Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells . Rheumatology (Oxford)49 ( 8 ), 1447 – 1460 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Halili MA , AndrewsMR , LabzinLIet al. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS . J. Leukoc. Biol.87 ( 6 ), 1103 – 1114 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Leus NG , van den BoschT , van der WoudenPEet al. HDAC1–3 inhibitor MS-275 enhances IL10 expression in in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice . Sci. Rep.7 , 45047 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Saraiva M , O’GarraA . The regulation of IL-10 production by immune cells . Nat. Rev. Immunol.10 ( 3 ), 170 – 181 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Leus NG , ZwindermanMR , DekkerFJ . Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-kappaB-mediated inflammation . Curr. Opin. Chem. Biol.33 , 160 – 168 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Leus NG , van der WoudenPE , van den BoschTet al. HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-kappaB p65 transcriptional activity . Biochem. Pharmacol.108 , 58 – 74 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Villagra A , ChengF , WangHWet al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance . Nat. Immunol.10 ( 1 ), 92 – 100 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Cheng F , LienlafM , Perez-VillarroelPet al. Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells . Mol. Immunol.60 ( 1 ), 44 – 53 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Castellucci M , RossatoM , CalzettiFet al. IL-10 disrupts the Brd4-docking sites to inhibit LPS-induced CXCL8 and TNF-alpha expression in monocytes: implications for chronic obstructive pulmonary disease . J. Allergy Clin. Immunol.136 ( 3 ), 781.e9 – 791.e9 ( 2015 ).
   Web of Science ®Google Scholar
• Liang Z , ZhangQ , ThomasCMet al. Impaired macrophage phagocytosis of bacteria in severe asthma . Respir. Res.15 , 72–9921 – 15–72 ( 2014 ).
   Web of Science ®Google Scholar
• Ariffin JK , das GuptaK , KapetanovicRet al. Histone deacetylase inhibitors promote mitochondrial reactive oxygen species production and bacterial clearance by human macrophages . Antimicrob. Agents Chemother.60 ( 3 ), 1521 – 1529 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Grausenburger R , BilicI , BoucheronNet al. Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production . J. Immunol.185 ( 6 ), 3489 – 3497 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wang C , CollinsM , KuchrooVK . Effector T cell differentiation: are master regulators of effector T cells still the masters?Curr. Opin. Immunol.37 , 6 – 10 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Yamagata T , MitaniK , OdaHet al. Acetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organs . EMBO J.19 ( 17 ), 4676 – 4687 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Colley T , MercadoN , KunoriYet al. Defective sirtuin-1 increases IL-4 expression through acetylation of GATA-3 in patients with severe asthma . J. Allergy Clin. Immunol.137 ( 5 ), 1595.e7 – 1597.e7 ( 2016 ).
   Web of Science ®Google Scholar
• Wing K , SakaguchiS . Regulatory T cells exert checks and balances on self tolerance and autoimmunity . Nat. Immunol.11 ( 1 ), 7 – 13 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Matsumoto K , InoueH , FukuyamaSet al. Frequency of Foxp3+CD4CD25+ T cells is associated with the phenotypes of allergic asthma . Respirology14 ( 2 ), 187 – 194 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Hamzaoui A , AmmarJ , HamzaouiK . Regulatory T cells in induced sputum of asthmatic children: association with inflammatory cytokines . Multidiscip Respir. Med.5 ( 1 ), 22 – 30 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Baru AM , GaneshV , KrishnaswamyJKet al. Absence of Foxp3+ regulatory T cells during allergen provocation does not exacerbate murine allergic airway inflammation . PLoS ONE7 ( 10 ), e47102 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Vale-Pereira S , Todo-BomA , GeraldesL , Schmidt-WeberC , AkdisCA , Mota-PintoA . FoxP3, GATA-3 and T-bet expression in elderly asthma . Clin. Exp. Allergy41 ( 4 ), 490 – 496 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Beier UH , AkimovaT , LiuY , WangL , HancockWW . Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells . Curr. Opin. Immunol.23 ( 5 ), 670 – 678 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Akimova T , BeierUH , LiuY , WangL , HancockWW . Histone/protein deacetylases and T-cell immune responses . Blood119 ( 11 ), 2443 – 2451 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kwon HS , LimHW , WuJ , SchnolzerM , VerdinE , OttM . Three novel acetylation sites in the Foxp3 transcription factor regulate the suppressive activity of regulatory T cells . J. Immunol.188 ( 6 ), 2712 – 2721 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Xiao Y , NagaiY , DengGet al. Dynamic interactions between TIP60 and p300 regulate FOXP3 function through a structural switch defined by a single lysine on TIP60 . Cell. Rep.7 ( 5 ), 1471 – 1480 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• de Zoeten EF , WangL , ButlerKet al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells . Mol. Cell. Biol.31 ( 10 ), 2066 – 2078 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Wang L , LiuY , HanRet al. FOXP3+ regulatory T cell development and function require histone/protein deacetylase 3 . J. Clin. Invest.125 ( 3 ), 1111 – 1123 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Wang L , de ZoetenEF , GreeneMI , HancockWW . Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells . Nat. Rev. Drug Discov.8 ( 12 ), 969 – 981 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Beier UH , WangL , HanR , AkimovaT , LiuY , HancockWW . Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms . Sci. Signal.5 ( 229 ), ra45 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Segretti MC , ValleriniGP , BrochierCet al. Thiol-based potent and selective HDAC6 inhibitors promote tubulin acetylation and T-regulatory cell suppressive function . ACS Med. Chem. Lett.6 ( 11 ), 1156 – 1161 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lucas JL , MirshahpanahP , Haas-StapletonE , AsadullahK , ZollnerTM , NumerofRP . Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors . Cell. Immunol.257 ( 1–2 ), 97 – 104 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Shen L , CiesielskiM , RamakrishnanSet al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models . PLoS ONE7 ( 1 ), e30815 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Bridle BW , ChenL , LemayCGet al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy . Mol. Ther.21 ( 4 ), 887 – 894 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Alcorn JF , CroweCR , KollsJK . TH17 cells in asthma and COPD . Annu. Rev. Physiol.72 , 495 – 516 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Aujla SJ , AlcornJF . T(H)17 cells in asthma and inflammation . Biochim. Biophys. Acta1810 ( 11 ), 1066 – 1079 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bullens DM , TruyenE , CoteurLet al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir. Res. 7 , 135 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Ivanov II , McKenzieBS , ZhouLet al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells . Cell126 ( 6 ), 1121 – 1133 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Wu Q , NieJ , GaoYet al. Reciprocal regulation of RORgammat acetylation and function by p300 and HDAC1 . Sci. Rep.5 , 16355 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Chen RY , FanYM , ZhangQet al. Estradiol inhibits Th17 cell differentiation through inhibition of RORgammaT transcription by recruiting the ERalpha/REA complex to estrogen response elements of the RORgammaT promoter . J. Immunol.194 ( 8 ), 4019 – 4028 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Glauben R , SonnenbergE , WetzelM , MascagniP , SiegmundB . Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo . J. Biol. Chem.289 ( 9 ), 6142 – 6151 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Glaser KB , StaverMJ , WaringJF , StenderJ , UlrichRG , DavidsenSK . Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines . Mol. Cancer Ther.2 ( 2 ), 151 – 163 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Mackmull MT , IskarM , ParcaLet al. Histone deacetylase inhibitors (HDACi) cause the selective depletion of bromodomain containing proteins (BCPs) . Mol. Cell. Proteomics14 ( 5 ), 1350 – 1360 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Halsall JA , TuranN , WiersmaM , TurnerBM . Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response . Epigenetics Chromatin8 , 29–015 – 0021–9 ; eCollection; 8, 29 ( 2015 ).
   Web of Science ®Google Scholar
• Luchenko VL , LitmanT , ChakrabortyARet al. Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin . Mol. Oncol.8 ( 8 ), 1379 – 1392 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bantscheff M , HopfC , SavitskiMMet al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes . Nat. Biotechnol.29 ( 3 ), 255 – 265 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Scholz C , WeinertBT , WagnerSAet al. Acetylation site specificities of lysine deacetylase inhibitors in human cells . Nat. Biotechnol.33 ( 4 ), 415 – 423 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lauffer BE , MintzerR , FongRet al. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability . J. Biol. Chem.288 ( 37 ), 26926 – 26943 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Becher I , DittmannA , SavitskiMM , HopfC , DrewesG , BantscheffM . Chemoproteomics reveals time-dependent binding of histone deacetylase inhibitors to endogenous repressor complexes . ACS Chem. Biol.9 ( 8 ), 1736 – 1746 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ito T , UmeharaT , SasakiKet al. Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors . Chem. Biol.18 ( 4 ), 495 – 507 ( 2011 ).
   PubMedGoogle Scholar
• Dinarello CA , FossatiG , MascagniP . Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer . Mol. Med.17 ( 5–6 ), 333 – 352 ( 2011 ).
   PubMed Web of Science ®Google Scholar